John Moquin, Beacon Partners Executive Consultant, explains the impact that the proposed Meaningful Use Stage 2 requirements could have on your organization and how to avoid costly and time-consuming adjustments down the road.
This article highlights:
- A high-level summary of the affected objectives
- Changes to Clinical Quality Measures (CQMs) reporting requirements
- How to prepare for impact